Amato J Giaccia

This inventor holds 20 USPTO granted patents and 19 published patent applications, plus 2 CIPO patents and 7 EPO patents. Top assignees: Leland Stanford Junior University, Aravive Biologics, Inc., Auckland Uniservices Limited. Active years: 1994-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Amato J Giaccia. Retrieved from https://idiyas.com/inventor/amato-j-giaccia

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 19)

% Patents Active = 65.0

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 7 (Patent Applications = 9)

Average Co-Inventor Count = 4.3

ph-index = 6

Forward Citations = 203(Granted Patents)

Location History:

Redwood City, CA (US) (1994)
Palo Alto, CA (US) (2014 - 2016)
Stanford, CA (US) (1997 - 2022)

Company Filing History:

18 out of 5,509

Leland Stanford Junior University

patents

4 out of 5

Aravive Biologics, Inc.

patents

3 out of 253

Auckland Uniservices Limited

Akso Biopharmaceutical, Inc.

patent

6. 2 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1994-2022

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11498955 - SPD-1 variant# FC fusion proteins (2022-11-15),

2. 11400133 - Receptor-based antagonists of the programmed cell death 1 (PD-1) pathway (2022-08-02),

3. 11136563 - Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy (2021-10-05),

4. 10876176 - Antifibrotic activity of GAS6 inhibitor (2020-12-29),

5. 10588938 - Receptor-based antagonists of the programmed cell death 1 (PD-1) pathway (2020-03-17),

6. 9879061 - Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis (2018-01-30),

7. 9822347 - Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy (2017-11-21),

8. 9296732 - Substituted benzamides and their uses (2016-03-29),

9. 9266947 - Inhibition of AXL signaling in anti-metastatic therapy (2016-02-23),

10. 9085570 - Substituted benzamides and their uses (2015-07-21),

11. 9079859 - Synthetic lethal targeting of glucose transport (2015-07-14),

12. 9074192 - Inhibition of AXL signaling in anti-metastatic therapy (2015-07-07),

13. 8680064 - ShRNA gene therapy for treatment of ischemic heart disease (2014-03-25),

14. 8618254 - Inhibition of AXL signaling in anti-metastatic therapy (2013-12-31),

15. 7378246 - Methods and compositions for regulating adipogenesis (2008-05-27),

Title: Innovations in Cancer Treatment: The Patents of Amato J Giaccia

Introduction

Amato J Giaccia is a distinguished inventor based in Stanford, California, known for his significant contributions to the field of cancer research and therapies. With an impressive portfolio of 20 patents, Giaccia has made remarkable advancements in the understanding and treatment of various cancers through innovative protein variants and compositions.

Latest Patents

Among his latest patents, Giaccia has developed SPD-1 variant Fc fusion proteins, which present novel receptor-based antagonists targeting the programmed cell death 1 (PD-1) pathway. This groundbreaking invention aims to alleviate cancer or infection in patients by administering a therapeutically effective amount of a composition comprising an isolated PD-1 variant polypeptide. The PD-1 variant polypeptide is engineered to inhibit the activity of PD-1, effectively interfering with its interaction with ligands such as PD-L1 and PD-L2.

Career Highlights

Giaccia's career is marked by his affiliations with esteemed institutions, such as Leland Stanford Junior University, where he has conducted pivotal research, and Aravive Biologics, Inc., where he has contributed to the development of therapeutic solutions for cancer. His relentless pursuit of innovation has garnered recognition within the scientific community, greatly influencing the landscape of cancer treatment.

Collaborations

In his innovative journey, Giaccia has collaborated with notable individuals, enhancing the scope of his research. His coworkers include Mihalis S Kariolis and Yu Rebecca Miao, who have played essential roles in driving forward the development of cancer-targeted therapies alongside his groundbreaking work.

Conclusion

Amato J Giaccia exemplifies the spirit of innovation through his extensive contributions to cancer research and therapeutics. His patents and collaborative efforts continue to pave the way for more effective cancer treatments, showcasing the vital role of inventors in advancing medical science.

Profile summary based on public USPTO records.